390 related articles for article (PubMed ID: 34370634)
21. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
22. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
[TBL] [Abstract][Full Text] [Related]
23. A series of molecular modeling techniques to reveal selective mechanisms of inhibitors to β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) and β-site amyloid precursor protein cleaving enzyme 2 (BACE2).
Li S; Zhao H; Li J; Hao J; Yu H
J Biomol Struct Dyn; 2021 May; 39(8):2824-2837. PubMed ID: 32276567
[TBL] [Abstract][Full Text] [Related]
24. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
25. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
Das B; Yan R
CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
[TBL] [Abstract][Full Text] [Related]
26. Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
Das S; Sengupta S; Chakraborty S
ACS Chem Neurosci; 2020 Nov; 11(21):3510-3522. PubMed ID: 33073981
[TBL] [Abstract][Full Text] [Related]
27. In silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine.
Huang HJ; Lee CC; Chen CY
Biomed Res Int; 2014; 2014():741703. PubMed ID: 24900984
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
29. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
30. Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.
Nadh AG; Revikumar A; Sudhakaran PR; Nair AS
Comput Biol Med; 2022 Jun; 145():105422. PubMed ID: 35354103
[TBL] [Abstract][Full Text] [Related]
31. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Velliquette RA; O'Connor T; Vassar R
J Neurosci; 2005 Nov; 25(47):10874-83. PubMed ID: 16306400
[TBL] [Abstract][Full Text] [Related]
32. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
33. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics.
Mouchlis VD; Melagraki G; Zacharia LC; Afantitis A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973122
[TBL] [Abstract][Full Text] [Related]
34. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
35. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
36. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.
Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y
Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408
[TBL] [Abstract][Full Text] [Related]
37. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
38. The β-Secretase BACE1 in Alzheimer's Disease.
Hampel H; Vassar R; De Strooper B; Hardy J; Willem M; Singh N; Zhou J; Yan R; Vanmechelen E; De Vos A; Nisticò R; Corbo M; Imbimbo BP; Streffer J; Voytyuk I; Timmers M; Tahami Monfared AA; Irizarry M; Albala B; Koyama A; Watanabe N; Kimura T; Yarenis L; Lista S; Kramer L; Vergallo A
Biol Psychiatry; 2021 Apr; 89(8):745-756. PubMed ID: 32223911
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent and selective dual cholinesterases and β-secretase inhibitors in pomegranate as a treatment for Alzheimer's disease.
Yousof Ali M; Zaib S; Jannat S; Khan I
Bioorg Chem; 2022 Dec; 129():106137. PubMed ID: 36108590
[TBL] [Abstract][Full Text] [Related]
40. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
